Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018

Karen M. MacDonald, Abhishek Kavati, Benjamin Ortiz, Abdulaziz Alhossan, Christopher S. Lee, Ivo Abraham

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma [SAA] in Europe). A 2016 review of 24 real-world effectiveness studies in SAA published between 2008–2015 concluded that omalizumab was associated with significant improvements in objective and subjective outcomes with benefits extending beyond 2 years. Several new real-world studies have been published since, bringing the total to 42 studies. Areas covered: This systematic review of 42 studies published since 2008 updates and extends the 2016 review on the real-word evidence on omalizumab in SAA. It offers greater granularity as to time windows within which outcomes are reported and includes studies extending well beyond 4 years post omalizumab initiation. Expert commentary: This review firmly establishes the short-term effectiveness of omalizumab in adolescent and adult patients with SAA at 1 year, and provides strong evidence of long-term effectiveness up to 4 years and emergent evidence of effectiveness beyond 4 years. In the aggregate, these 42 studies underscore the long-term effectiveness of omalizumab in terms of: reducing exacerbations and symptoms, achieving asthma control, improving lung function, enhancing quality of life, decreasing emergency department visits and hospitalizations, and promoting concomitant medication-sparing.

Original languageEnglish (US)
Pages (from-to)553-569
Number of pages17
JournalExpert Review of Clinical Immunology
Volume15
Issue number5
DOIs
StatePublished - May 4 2019

    Fingerprint

Keywords

  • Allergic asthma
  • IgE
  • omalizumab
  • real-word effectiveness
  • systematic review

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this